GLP-1 & Incretin Science

Why Biopsy Endpoints Make Liver Trials Hard

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

MASH trials measure histological change on liver biopsy: resolution of steatohepatitis and improvement in fibrosis. These are scored by pathologists, carry documented inter-observer variability, and are surrogates for outcomes no trial can follow to completion.

Key facts

Endpoint source
Liver biopsy
Scored by
Pathologist judgement
Known issue
Inter-observer variability
Mitigation
Central reading, blinded
Endpoint status
Surrogate, not clinical outcome
Sampling issue
Biopsy samples a fraction of the organ

What is actually being measured

Two composite histological endpoints the field has converged on: resolution of steatohepatitis without worsening of fibrosis, and improvement in fibrosis without worsening of steatohepatitis. Both combine several scored features into a binary outcome, which is a considerable amount of judgement compressed into a yes or no.

The variability problem

Two competent pathologists reading the same slide do not always agree, and the same pathologist reading it twice does not always agree with themselves. That variability is well documented and it adds noise to the endpoint, which reduces a trial's power to detect a real treatment effect and can obscure modest benefits.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why sampling makes it worse

A needle biopsy retrieves a small fraction of a large organ, and MASH is not uniformly distributed through the liver. Two samples from the same patient can score differently because the disease differs between sites, not because anything changed. This is a limitation of the measurement rather than of the analysis.

How trials manage it

Central reading by a small panel, blinded to treatment assignment and often to sequence, with paired biopsies read together. That controls the variability rather than eliminating it, and it is why the reading methodology in a MASH trial deserves attention: a well-run central read is a substantive part of the evidence.

Why they are surrogates at all

What matters clinically is cirrhosis, liver failure, transplant and death, which take decades. No trial can wait. Histology is used because it lies on the path to those outcomes and can be measured in a few years. It is a reasonable compromise, but still a compromise.

The consequence for approvals

Regulators grant accelerated approvals on surrogate endpoints with confirmatory outcome evidence required afterwards. So a MASH approval is a conditional statement about a probable benefit, not a settled one, and that distinction almost never survives into coverage of these decisions.

Frequently asked questions

Why do MASH trials need biopsies?

Because the endpoints are histological: inflammation, ballooning and fibrosis scored on tissue. No blood test substitutes for them at present.

How reliable is histological scoring?

It carries documented inter-observer variability, and biopsy sampling captures only a fraction of a non-uniformly affected organ.

Why are these endpoints accepted?

Because the real outcomes (cirrhosis, liver failure, death) take decades, and histology lies on the path to them and can be measured in years.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.